AAAAAA

   
Results: 1-7 |
Results: 7
ACTIVITIES OF DAILY LIVING AS AN OUTCOME MEASURE IN CLINICAL-TRIALS OF DEMENTIA DRUGS - POSITION PAPER FROM THE INTERNATIONAL WORKING GROUPON HARMONIZATION OF DEMENTIA DRUG GUIDELINES
Authors: GAUTHIER S BODICK N ERZIGKEIT E FELDMAN H GELDMACHER DS HUFF J MOHS R ORGOGOZO JM ROGERS S
Citation: S. Gauthier et al., ACTIVITIES OF DAILY LIVING AS AN OUTCOME MEASURE IN CLINICAL-TRIALS OF DEMENTIA DRUGS - POSITION PAPER FROM THE INTERNATIONAL WORKING GROUPON HARMONIZATION OF DEMENTIA DRUG GUIDELINES, Alzheimer disease and associated disorders, 11, 1997, pp. 6-7
OBJECTIVE PSYCHOMETRIC TESTS IN CLINICAL-TRIALS OF DEMENTIA DRUGS - POSITION PAPER FROM THE INTERNATIONAL WORKING GROUP ON HARMONIZATION OFDEMENTIA DRUG GUIDELINES
Authors: FERRIS SH LUCCA U MOHS R DUBOIS B WESNES K ERZIGKEIT H GELDMACHER D BODICK N
Citation: Sh. Ferris et al., OBJECTIVE PSYCHOMETRIC TESTS IN CLINICAL-TRIALS OF DEMENTIA DRUGS - POSITION PAPER FROM THE INTERNATIONAL WORKING GROUP ON HARMONIZATION OFDEMENTIA DRUG GUIDELINES, Alzheimer disease and associated disorders, 11, 1997, pp. 34-38
PROTOCOLS TO DEMONSTRATE SLOWING OF ALZHEIMER-DISEASE PROGRESSION - POSITION PAPER FROM THE INTERNATIONAL WORKING GROUP ON HARMONIZATION OFDEMENTIA DRUG GUIDELINES
Authors: BODICK N FORETTE F HADLER D HARVEY RJ LEBER P MCKEITH IG RIEKKINEN PJ ROSSOR MN SCHELTENS P SHIMOHAMA S SPIEGEL R TANAKA S THAL LJ URATA Y WHITEHOUSE P WILCOCK G
Citation: N. Bodick et al., PROTOCOLS TO DEMONSTRATE SLOWING OF ALZHEIMER-DISEASE PROGRESSION - POSITION PAPER FROM THE INTERNATIONAL WORKING GROUP ON HARMONIZATION OFDEMENTIA DRUG GUIDELINES, Alzheimer disease and associated disorders, 11, 1997, pp. 50-53
QUALITY-OF-LIFE ASSESSMENT IN DEMENTIA DRUG DEVELOPMENT - POSITION PAPER FROM THE INTERNATIONAL WORKING GROUP ON HARMONIZATION OF DEMENTIA DRUG GUIDELINES
Authors: WHITEHOUSE PJ ORGOGOZO JM BECKER RE GAUTHIER S PONTECORVO M ERZIGKEIT H ROGERS S MOHS RC BODICK N BRUNO G DALBIANCO P
Citation: Pj. Whitehouse et al., QUALITY-OF-LIFE ASSESSMENT IN DEMENTIA DRUG DEVELOPMENT - POSITION PAPER FROM THE INTERNATIONAL WORKING GROUP ON HARMONIZATION OF DEMENTIA DRUG GUIDELINES, Alzheimer disease and associated disorders, 11, 1997, pp. 56-60
EFFECTS OF CENTRAL MUSCARINIC-1 RECEPTOR STIMULATION ON BLOOD-PRESSURE REGULATION
Authors: MEDINA A BODICK N GOLDBERGER AL MACMAHON M LIPSITZ LA
Citation: A. Medina et al., EFFECTS OF CENTRAL MUSCARINIC-1 RECEPTOR STIMULATION ON BLOOD-PRESSURE REGULATION, Hypertension, 29(3), 1997, pp. 828-834
BRAIN PROTON MAGNETIC-RESONANCE SPECTROSCOPY (H-1-MRS) IN ALZHEIMERS-DISEASE - CHANGES AFTER TREATMENT WITH XANOMELINE, AN M-1 SELECTIVE CHOLINERGIC AGONIST
Authors: SATLIN A BODICK N OFFEN WW RENSHAW PF
Citation: A. Satlin et al., BRAIN PROTON MAGNETIC-RESONANCE SPECTROSCOPY (H-1-MRS) IN ALZHEIMERS-DISEASE - CHANGES AFTER TREATMENT WITH XANOMELINE, AN M-1 SELECTIVE CHOLINERGIC AGONIST, The American journal of psychiatry, 154(10), 1997, pp. 1459-1461
TREATMENT OF ALZHEIMERS-DISEASE WITH XANOMELINE, AN M1 SELECTIVE CHOLINERGIC AGONIST - BRAIN MAGNETIC-RESONANCE SPECTROSCOPY (MRS) CHANGES
Authors: SATLIN A RENSHAW PF BODICK N
Citation: A. Satlin et al., TREATMENT OF ALZHEIMERS-DISEASE WITH XANOMELINE, AN M1 SELECTIVE CHOLINERGIC AGONIST - BRAIN MAGNETIC-RESONANCE SPECTROSCOPY (MRS) CHANGES, Psychopharmacology bulletin, 32(3), 1996, pp. 508-508
Risultati: 1-7 |